Personalized Cell Therapy
Pharmaceutical Technology spoke with Peter Walters, director of advanced therapies at CRB, about point-of-use manufacturing for cell and gene therapy.
PharmTech: How can point-of-use drug manufacturing impact the cell and gene therapy industry?
Walters (CRB): Point-of-use manufacturing could have the potential to improve the personalized cell therapy industry. These therapies suffer from transport logistical issues in moving patient cells from the clinic to the manufacturing facility, and then back again. This transport causes delays to the delivery of the therapy to the patient, introduces cold chain and sheer sensitivity shipping hurdles, and lengthens the time the cells are forced to be stored in a non-ideal state. All of these ultimately contribute to lowering the efficacy of the therapy and the chances the patient will have a successful recovery. Moving the manufacturing activity adjacent to the patient could dramatically reduce these issues, potentially improving the therapy’s effectiveness.